2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

2seventy bio, Inc. (NASDAQ:TSVT) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.20.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday.

2seventy bio Trading Down 7.0 %

Shares of 2seventy bio stock opened at $2.66 on Monday. 2seventy bio has a 1 year low of $2.29 and a 1 year high of $5.99. The company has a market cap of $137.22 million, a P/E ratio of -1.43 and a beta of 1.73. The stock has a 50-day moving average price of $2.60 and a 200 day moving average price of $3.70.

Institutional Trading of 2seventy bio

Institutional investors have recently modified their holdings of the company. BBR Partners LLC lifted its position in 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after purchasing an additional 155,000 shares during the period. Geode Capital Management LLC raised its stake in shares of 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after buying an additional 13,144 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of 2seventy bio during the 3rd quarter worth about $64,000. FMR LLC boosted its position in shares of 2seventy bio by 22.0% during the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after acquiring an additional 26,738 shares in the last quarter. Finally, State Street Corp boosted its position in shares of 2seventy bio by 1.5% during the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after acquiring an additional 15,638 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.